Search Results

But for Ajay Yekkirala, that closed door lit the fuse for a career that would reimagine GPCR therapeutics was a scientific journey that now spans two biotech startups, and a bold reimagining of GPCR-targeted therapeutics story — one that begins with a failed goal, but ends up reshaping how we think about GPCR-targeted therapeutics Blue Therapeutics: Turning GPCR Biology Into a Business Ajay’s academic training planted the seeds for what would later become Blue Therapeutics, a startup he co-founded to develop non-addictive pain medications

August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of effective medicines many GPCRs remain poorly characterised. GPR84 is an example. Expression of GPR84 is strongly up regulated in immune cells in a range of pro-inflammatory settings and clinical trials to treat idiopathic pulmonary fibrosis are currently ongoing using ligands with differing levels of selectivity and affinity as GPR84 antagonists. Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation of the lower gut there is emerging interest in defining if agonists of GPR84 might find utility in conditions in which regulation of metabolism or energy sensing is compromised. Here, we consider the physiological and pathological expression profile of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological tool compounds to study its broader role and biology. " Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

August 2022 A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets

VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic

Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic

March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics, Inc.

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet

We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."

August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:

Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve genomic and transcriptomic profiles of ORs in glioma, we suggest that ORs are potential biomarkers and therapeutic

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.

Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic

Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic

Phase 1 studies in Japan with JNJ-40411813 (ADX71149) "Geneva, Switzerland, November 15, 2021 – Addex Therapeutics

Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics

, GPCRs, and more RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic essential for rhodopsin trafficking to vertebrate photoreceptor outer segments Industry News Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership Sosei Heptares Announces Submission for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives

This week's highlight: Congratulations to the GPCR Therapeutics team for their publication on improving Orion's COO, Shared Innovative Insights at LSBC Central European Life Science Investment Conference GPCR Therapeutics Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 Sosei Heptares Late-Stage Development Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Meetings, and Webinars November 2 - 4, 2023 | GPCR Retreat- Registration Closed November 10, 2023 | Sosei Heptares

Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors.

2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Research Council (ERC) Addex Reports Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

and uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F Industry News Sosei Heptares Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD) Domain Therapeutics and Chime Biologics Form Manufacturing Pact for Antibody Cancer Immunotherapy Sosei Heptares Regains

Allosteric Modulators in Neurological Disorders at Jefferies Healthcare Conference in London Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months